Cargando…
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effe...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/ https://www.ncbi.nlm.nih.gov/pubmed/34479924 http://dx.doi.org/10.1136/jitc-2021-002627 |
_version_ | 1783748937748840448 |
---|---|
author | Bayless, Nicholas L Bluestone, Jeffrey A Bucktrout, Samantha Butterfield, Lisa H Jaffee, Elizabeth M Koch, Christian A Roep, Bart O Sharpe, Arlene H Murphy, William J Villani, Alexandra-Chloé Walunas, Theresa L |
author_facet | Bayless, Nicholas L Bluestone, Jeffrey A Bucktrout, Samantha Butterfield, Lisa H Jaffee, Elizabeth M Koch, Christian A Roep, Bart O Sharpe, Arlene H Murphy, William J Villani, Alexandra-Chloé Walunas, Theresa L |
author_sort | Bayless, Nicholas L |
collection | PubMed |
description | Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effective cancer immunotherapy agents, including antibody blockade of the cytotoxic T-lymphocyte-associated protein 4 and programmed death protein 1/programmed-death ligand 1 pathways. To develop an action plan on the key elements needed to unravel and understand the key mechanisms driving irAEs, the Society for Immunotherapy for Cancer and the American Association for Cancer Research partnered to bring together research and clinical experts in cancer immunotherapy, autoimmunity, immune regulation, genetics and informatics who are investigating irAEs using animal models, clinical data and patient specimens to discuss current strategies and identify the critical next steps needed to create breakthroughs in our understanding of these toxicities. The genetic and environmental risk factors, immune cell subsets and other key immunological mediators and the unique clinical presentations of irAEs across the different organ systems were the foundation for identifying key opportunities and future directions described in this report. These include the pressing need for significantly improved preclinical model systems, broader collection of biospecimens with standardized collection and clinical annotation made available for research and integration of electronic health record and multiomic data with harmonized and standardized methods, definitions and terminologies to further our understanding of irAE pathogenesis. Based on these needs, this report makes a set of recommendations to advance our understanding of irAE mechanisms, which will be crucial to prevent their occurrence and improve their treatment. |
format | Online Article Text |
id | pubmed-8420733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84207332021-09-22 Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR Bayless, Nicholas L Bluestone, Jeffrey A Bucktrout, Samantha Butterfield, Lisa H Jaffee, Elizabeth M Koch, Christian A Roep, Bart O Sharpe, Arlene H Murphy, William J Villani, Alexandra-Chloé Walunas, Theresa L J Immunother Cancer Review Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effective cancer immunotherapy agents, including antibody blockade of the cytotoxic T-lymphocyte-associated protein 4 and programmed death protein 1/programmed-death ligand 1 pathways. To develop an action plan on the key elements needed to unravel and understand the key mechanisms driving irAEs, the Society for Immunotherapy for Cancer and the American Association for Cancer Research partnered to bring together research and clinical experts in cancer immunotherapy, autoimmunity, immune regulation, genetics and informatics who are investigating irAEs using animal models, clinical data and patient specimens to discuss current strategies and identify the critical next steps needed to create breakthroughs in our understanding of these toxicities. The genetic and environmental risk factors, immune cell subsets and other key immunological mediators and the unique clinical presentations of irAEs across the different organ systems were the foundation for identifying key opportunities and future directions described in this report. These include the pressing need for significantly improved preclinical model systems, broader collection of biospecimens with standardized collection and clinical annotation made available for research and integration of electronic health record and multiomic data with harmonized and standardized methods, definitions and terminologies to further our understanding of irAE pathogenesis. Based on these needs, this report makes a set of recommendations to advance our understanding of irAE mechanisms, which will be crucial to prevent their occurrence and improve their treatment. BMJ Publishing Group 2021-09-03 /pmc/articles/PMC8420733/ /pubmed/34479924 http://dx.doi.org/10.1136/jitc-2021-002627 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Bayless, Nicholas L Bluestone, Jeffrey A Bucktrout, Samantha Butterfield, Lisa H Jaffee, Elizabeth M Koch, Christian A Roep, Bart O Sharpe, Arlene H Murphy, William J Villani, Alexandra-Chloé Walunas, Theresa L Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
title | Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
title_full | Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
title_fullStr | Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
title_full_unstemmed | Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
title_short | Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
title_sort | development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from sitc and aacr |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/ https://www.ncbi.nlm.nih.gov/pubmed/34479924 http://dx.doi.org/10.1136/jitc-2021-002627 |
work_keys_str_mv | AT baylessnicholasl developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT bluestonejeffreya developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT bucktroutsamantha developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT butterfieldlisah developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT jaffeeelizabethm developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT kochchristiana developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT roepbarto developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT sharpearleneh developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT murphywilliamj developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT villanialexandrachloe developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT walunastheresal developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr |